20 articles
Isoquercitrin reshapes gut bacteria and tryptophan metabolism to reduce arterial plaque, pointing to a novel gut-heart therapeutic pathway.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
A 330-patient multicenter RCT tests whether thymosin ฮฑ1 can curb immune dysregulation and organ dysfunction after acute type A aortic dissection repair.
Breakthrough treatment works through multiple mechanisms beyond the lungs, enhancing oxygen delivery and muscle function.
Novel liposome therapy delivers miR-10a to atherosclerotic plaques, reprogramming inflammatory macrophages and reducing disease progression in mice.
New research shows inhibiting fatty acid synthase prevents cardiac hypertrophy and restores heart function in multiple models.
Scientists identify GPRASP1 as a key guardian of pulmonary vascular health, opening a potential drug target for PH-HFpEF.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
Post-analysis of major trial shows extended apixaban treatment may prevent superficial vein thrombosis in patients with ongoing clotting risks.
The first disease-specific treatment for Barth syndrome gains FDA accelerated approval, targeting mitochondrial dysfunction to restore muscle strength.
Elevated oxidized phospholipids independently predict major cardiac events after ACS, and alirocumab abolishes that risk signal.
New research shows knocking out the AhR receptor significantly reduces arterial plaque formation and improves cholesterol levels.
NEJM publishes erratum for Phase 2a study of baxdrostat in primary aldosteronism treatment
Sotatercept emerges as potential treatment for combined pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction.
In 2,040 coronary angiography patients, OxPL-apoB predicted MI-free survival but showed no link to platelet reactivity, implicating Lp(a) as the key mediator.
TREM-1 inhibitor LR12 reduced harmful plaque formation in stents by nearly 50% without affecting healing in rabbit studies.
New research reveals how modulating immune cells in arterial plaques could reduce cardiovascular disease progression.
New research reveals how good cholesterol forms diverse protective particles through a key cellular transporter mechanism.
Merck's CETP inhibitor anacetrapib was evaluated alongside statin therapy to assess LDL-C lowering and HDL-C raising in hypercholesterolemia patients.
